Osteoporosis in the European Union: medical management, epidemiology and economic burden

被引:1529
作者
Hernlund, E. [1 ]
Svedbom, A. [1 ]
Ivergard, M. [1 ]
Compston, J. [2 ]
Cooper, C. [3 ,4 ]
Stenmark, J. [5 ]
McCloskey, E. V. [6 ,7 ]
Jonsson, B. [8 ]
Kanis, J. A. [7 ,9 ]
机构
[1] OptumInsight, Stockholm, Sweden
[2] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England
[3] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England
[4] Univ Oxford, Inst Musculoskeletal Sci, NIHR Musculoskeletal Biomed Res Unit, Oxford, England
[5] Int Osteoporosis Fdn, Nyon, Switzerland
[6] Univ Sheffield, No Gen Hosp, Acad Unit Bone Metab, Sheffield S10 2RX, S Yorkshire, England
[7] Univ Sheffield, WHO Collaborating Ctr Metab Bone Dis, Sheffield S10 2RX, S Yorkshire, England
[8] Stockholm Sch Econ, S-11383 Stockholm, Sweden
[9] Univ Sheffield, Sch Med, WHO Collaborating Ctr Metab Bone Dis, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England
基金
英国医学研究理事会;
关键词
BONE-MINERAL DENSITY; HIP FRACTURE INCIDENCE; VERTEBRAL COMPRESSION FRACTURES; QUALITY-OF-LIFE; HIGH-TRAUMA FRACTURES; COST-EFFECTIVENESS; POSTMENOPAUSAL WOMEN; INTERVENTION THRESHOLDS; EXCESS MORTALITY; ELDERLY-WOMEN;
D O I
10.1007/s11657-013-0136-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27). Introduction Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for affected patients and substantial costs to society. The aim of this report was to characterize the burden of osteoporosis in the EU27 in 2010 and beyond. Methods The literature on fracture incidence and costs of fractures in the EU27 was reviewed and incorporated into a model estimating the clinical and economic burden of osteoporotic fractures in 2010. Results Twenty-two million women and 5.5 million men were estimated to have osteoporosis; and 3.5 million new fragility fractures were sustained, comprising 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and other femoral fractures). The economic burden of incident and prior fragility fractures was estimated at (sic)37 billion. Incident fractures represented 66 % of this cost, long-term fracture care 29 % and pharmacological prevention 5 %. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining. Conclusions In spite of the high social and economic cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by the aging populations, the use of pharmacological interventions to prevent fractures has decreased in recent years, suggesting that a change in healthcare policy is warranted.
引用
收藏
页数:115
相关论文
共 386 条
  • [51] VERTEBRAL DEFORMITIES AS PREDICTORS OF NON-VERTEBRAL FRACTURES
    BURGER, H
    VANDAELE, PLA
    ALGRA, D
    HOFMAN, A
    GROBBEE, DE
    SCHUTTE, HE
    BIRKENHAGER, JC
    POLS, HAP
    [J]. BRITISH MEDICAL JOURNAL, 1994, 309 (6960) : 991 - 992
  • [52] NEW TREATMENT MODALITIES IN OSTEOPOROSIS
    Canalis, Ernesto
    [J]. ENDOCRINE PRACTICE, 2010, 16 (05) : 855 - 863
  • [53] Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events
    Capri, S
    Perlini, S
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (06) : 913 - 921
  • [54] The impact of compliance with osteoporosis therapy on fracture rates in actual practice
    Caro, JJ
    Ishak, KJ
    Huybrechts, KF
    Raggio, G
    Naujoks, C
    [J]. OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) : 1003 - 1008
  • [55] Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey
    Carr, A. J.
    Thompson, P. W.
    Cooper, C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) : 1638 - 1644
  • [56] Risk of mortality following clinical fractures
    Cauley, JA
    Thompson, DE
    Ensrud, KC
    Scott, JC
    Black, D
    [J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 (07) : 556 - 561
  • [57] Official Positions for FRAX® Clinical Regarding International Differences
    Cauley, Jane A.
    El-Hajj Fuleihan, Ghada
    Arabi, Asma
    Fujiwara, Saeko
    Ragi-Eis, Sergio
    Calderon, Andrew
    Chionh, Siok Bee
    Chen, Zhao
    Curtis, Jeffrey R.
    Danielson, Michelle E.
    Hanley, David A.
    Kroger, Heikki
    Kung, Annie W. C.
    Lesnyak, Olga
    Nieves, Jeri
    Pluskiewicz, Wojciech
    El Rassi, Rola
    Silverman, Stuart
    Schott, Anne-Marie
    Rizzoli, Rene
    Luckey, Marjorie
    [J]. JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 240 - 262
  • [58] Cawston H, 2012, Arch Osteoporos, V7, P237
  • [59] Mortality after all major types of osteoporotic fracture in men and women: an observational study
    Center, JR
    Nguyen, TV
    Schneider, D
    Sambrook, PN
    Eisman, JA
    [J]. LANCET, 1999, 353 (9156) : 878 - 882
  • [60] A MODEL OF LIFETIME OSTEOPOROSIS IMPACT
    CHRISCHILLES, EA
    BUTLER, CD
    DAVIS, CS
    WALLACE, RB
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (10) : 2026 - 2032